GlassScriptPhysician profile
April N Turner
NPI 1821760018
$1,669.83
in general payments reported to CMS, 2019-2025
21 companies · $557 in 2025
The $557 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $238 · 2023: $236 · 2024: $639 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $414.77 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.45 | 2022-2025 | Xifaxan |
| Novo Nordisk INC | $174.28 | 2022-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $116.23 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $107.07 | 2022-2024 | |
| Abbvie INC. | $90.60 | 2024-2025 | |
| Pfizer INC. | $72.76 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $72.46 | 2022-2023 | |
| Glaxosmithkline, LLC. | $56.81 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $54.97 | 2022-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.73 | 2022-2024 | Jardiance |
| Agios Pharmaceuticals, INC. | $46.39 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $42.03 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $34.58 | 2025 | Rexulti |
| Boston Scientific Corporation | $31.39 | 2024-2025 | Bodyguardian |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.91 | 2024 | Cologuard Collection Kit |
| Cipher Pharmaceuticals US LLC | $23.27 | 2025 | Spinosad, Natroba |
| Kowa Pharmaceuticals America, INC. | $21.90 | 2022 | |
| Axsome Therapeutics, INC. | $17.73 | 2025 | Auvelity |
| Mylan Specialty L.P. | $15.54 | 2023 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.96 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.